Diagnostic performance of Prof. Valmed, ChatGPT-5 Thinking, and OpenEvidence in rheumatology: A comparative evaluation
Abstract
To compare the diagnostic performance of a subscription-based medical large language model (LLM) certified as a medical device (Prof. Valmed), a subscription-based general-purpose LLM (ChatGPT-5 Thinking), and a freely accessible medical LLM (OpenEvidence). Sixty vignettes covering rare rheumatic diseases and differential diagnoses were entered using a standardized prompt to generate five top diagnoses and respective diagnostic probabilities. Blinded rheumatologists categorized suggested diagnoses as identical, plausible, or diagnostically different. Diagnostic accuracy was assessed using proportions of identical and plausible diagnoses and a total diagnostic score. Analyses were descriptive. Group differences for the proportion of identical top diagnoses were explored using Cochran’s Q test and post-hoc McNemar tests. Processing time was recorded. OpenEvidence produced the highest proportion of identical top diagnoses (35.0%), followed by ChatGPT-5 Thinking (26.7%) and Prof. Valmed (23.3%); however, pairwise differences were not statistically significant. ChatGPT-5 Thinking achieved the highest total diagnostic score (226), followed by OpenEvidence (221) and Prof. Valmed (212). All systems showed markedly higher diagnostic probabilities for identical versus different diagnoses. Mean processing times ranged from 20 to 36 s. All three systems demonstrated broadly comparable diagnostic accuracy and processing times. Further benchmarking that incorporates additional evaluation dimensions is essential to inform safe and effective use of LLM-based clinical support.
Fields of Study & Subjects
Artificial Intelligence in Healthcare and Education
Clinical Reasoning and Diagnostic Skills
Rheumatoid Arthritis Research and Therapies
Publication details
- Journal / source
- Rheumatology International
- Publisher
- Springer Science and Business Media LLC
- Volume
- 46
- Issue
- 1
- Pages
- 31–31
- Publication date
- 10 January 2026
- Language
- EN